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Long-term non-progressive HIV infection, characterized by low but detectable viral load and stable CD4 counts in the absence of
antiviral therapy, is observed in about 5% of HIV-infected patients. Here we identified four therapy naı¨ve individuals who are strongly
seropositive for HIV-1 but who lack evidence of detectable HIV p24 antigen, plasma RNA, and proviral DNA in routine diagnostic testing.
With an ultrasensitive PCR, we established that frequencies of pol proviral DNA sequences were as low as 0.2–0.5 copies/106 PBMC.
HIV could not be isolated using up to 30  106 patient PBMC. One individual was heterozygous for CCR5 D32, but CCR5 expression on
CD4+ T cells was normal to high in all four individuals. In vitro R5 and X4 HIV-1 susceptibility of CD8-depleted PBMC of all study
subjects was significantly lower than the susceptibility of CD8-depleted PBMC of healthy blood donors. All individuals expressed
protective HLA-B*58s alleles and showed evidence of HIV-specific cellular immunity either by staining with HLA-B*57 tetramers folded
with an HIV RT or gag peptide or after stimulation with HIV-1 p24 gag, RT, or nef peptides in ELIspot analysis. HIV-specific CD4+ T
helper cells were demonstrated by proliferation of CD4+ T cells and intracellular staining for IL-2 and IFNg after stimulation with an HIV-
gag peptide pool. Sera of all individuals showed antibody-mediated neutralization of both R5 and X4 HIV-1 variants. These data implicate
that very low-level antigen exposure is sufficient for sustained HIV-specific immunity and suggest the possibility of a multi-factorial
control of HIV infection.
D 2005 Elsevier Inc. All rights reserved.Keywords: HIV infection; Immunity; AntigenIntroduction
The clinical course of HIV-1 infection can be highly
variable and is characterized by a gradual and progressive
loss of CD4+ T cells and cellular immunity, eventually0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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antiviral therapy, AIDS develops typically within 8–10
years after infection, but occasionally more rapid disease
progression or rather an asymptomatic phase of more than
15 years may also occur.
Both viral and host factors can influence the course of
infection. Disease progression is accelerated in individu-
als with syncytium inducing CXCR4 using (SI/X4)
viruses (Koot et al., 1993), hemophiliacs infected with
nef deleted attenuated virus variants have an extremely
slow disease progression (Learmont et al., 1999), and005) 70 – 80
Fig. 1. Demonstration of HIV-specific antibodies by LIATEK assay.
LIATEK assay with sera from subjects 1 to 4 showing reactivity with
HIV-1 proteins gp120, gp41, p31, p24, and p17 and no reactivity with HIV-
2 proteins sgp105 and gp36. The top band contains streptavidin and serves
as an internal control for the blot reaction.
Table 1
Serology, virology, immune diagnostics, and host genetics
Test Subject 1 Subject 2 Subject 3 Subject 4
HIV-1 Western blot + + + +
aHIV-1 EIA + + + +
Plasma HIV RNA
(copies/ml plasma)
<50 <50 <50 <50
HIV antigen
(pg/ml plasma)
<60 <60 <60 <60
HIV DNA
(copies/0.5 ml
whole blood)
<10 <10 <10 <10
Replication competent
HIV-1 (per 106 CD4+
HLA-DR T cells)
<0.2 NTa NT <0.2
CD4 count: cells/mm3
At first measurement 820 923 873 384
At end of follow up 710 1063 820 930
Range 480–830 827–1268 640–911 336–930
Median 655 1032 847 426
CCR5 genotype wt/wtb wt/wt D32/wt wt/wt
CCR2 genotype wt/wt wt/wt wt/wt wt/wt
CCR5+ cells within
CD4+ population
30.6% 32.0% 12.3% 36%
HLA class I genotype A01/A03 A02/A30 A23/A68 A11/A30
B3501/B57 B51/B57 B44/B58 B3501/B57
Cw4/Cw6 Cw14/Cw18 Cw2/Cw7 Cw4/Cw18
a NT, not tested.
b wt, wild type.
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virus variants with slow in vitro replication kinetics
(Blaak et al., 1998).
Concerning host genetic factors, homozygosity for a 32-
base pair deletion in the CCR5 gene (CCR5 D32) provides
protection against infection with CCR5 using (R5) HIV-1
variants which generally establish infection. Heterozygosity
for this deletion, as well as a valine to isoleucine
substitution in CCR2 (CCR2 64I), has been associated
with delayed disease progression (Ioannidis et al., 2001).
Certain specific human leukocyte antigen (HLA) alleles
(Kaslow et al., 1996; Migueles et al., 2000) and the
capacity of a host to generate a strong HIV-specific immune
response have also been correlated with prolonged asymp-
tomatic survival (Klein et al., 1995; Pontesilli et al., 1999;
Rosenberg et al., 1997).
Despite this multitude of factors that provide relative
protection from disease progression, complete natural
control of HIV-1 infection has never been reported. Indeed,
even LTNP have low but continuously detectable viral load
and in the Amsterdam cohort, 95% of originally defined
LTNP show signs of disease progression or have progressed
to disease (Goudsmit et al., 2002).
Sustained suppression of HIV-1 may in principle be
achieved by life-long therapy but the need for optimal
adherence and the occurrence of adverse effects associated
with treatment are major obstacles. New treatment strategies
for HIV-1 infection are therefore warranted and could be
based on natural control mechanisms of HIV-1 infection. In
the present study we for the first time provide evidence for
sustained control of HIV-1 infection, to the level of
undetectable HIV-1 RNA in plasma and extremely low
proviral DNA load, in four antiviral therapy naive HIV-
seropositive individuals.Results
HIV-seropositive individuals with extremely low-level
proviral DNA
We studied four individuals who tested positive in
ELISA and Western blot for HIV-1 antibodies but who
lacked detectable proviral DNA in routine diagnostic
testing. In all 4 individuals, the presence of high HIV-
specific antibody levels could be confirmed in a LIATEK
immunoblot assay (Fig. 1). CD4+ lymphocyte counts in
subjects 1–3 were measured repeatedly since 1996 and
were always in the normal range during follow-up. CD4+
lymphocyte counts in subject 4 were monitored since 2000
and were always stable and around 400 cells/Al blood
(Table 1). None of the four individuals ever received
antiretroviral therapy. HIV-1 RNA load and p24 antigen
load in plasma were frequently measured using different
methods and always below the lower limit of quantifica-
tion (<50 RNA copies/ml plasma and <60 pg p24/ml
plasma, respectively, data not shown), which is extremely
rare in HIV-seropositive individuals not receiving antiviral
therapy.
Several attempts were made to isolate replication
competent virus from subjects 1 and 3. However,
replication competent virus could not be isolated, not even
from the previously described cellular reservoir of HLA-
DR CD4+ T cells (Wong et al., 1997; Finzi et al., 1997),
and not even when an input of 20  106 purified HLA-
Fig. 2. Relative HIV-1 susceptibility of CD8-depleted PBMC from study
subjects and healthy blood donors. Each dot indicates the infectious titer,
expressed as log10 TCID50 per ml virus stock, as established by R5 HIV-1
strain JR-CSF, R5X4 HIV-1 biological virus clone 13B1 and X4 biological
virus clone X1.A1 from subject ACH208, R5X4 HIV-1 biological virus
clone 3.1 from subject ACH320, R5X4 HIV-1 strain HAN2 and X4 HIV-1
isolate IIIB on CD8-depleted PHA-stimulated PBMC of the four study
subjects or healthy blood donor volunteers. Subjects 1–4 are indicated on
the x-axis. Controls represent PBMC of three healthy donors and a PBMC
pool, which consists of a mix of PBMC of ten healthy blood donors. Lines
represent median values.
N. Kloosterboer et al. / Virology 339 (2005) 70–8072DR CD4+ cells was used for multiple co-cultivations in
the virus isolation procedure (Table 1). Interestingly, all
four individuals also lacked detectable proviral DNA in
their PBMC in routine diagnostic testing (limit of
detection: 10 HIV DNA copies/500 Al whole blood).
Using an ultrasensitive PCR with a limit of detection of 1
copy per 500 ng DNA (Koning et al., 2005) we were able
to amplify a 128-base pair pol fragment from PBMC DNA
from all 4 individuals (data not shown). For subjects 1–4,
respectively, 8 out of 50, 5 out of 100, 8 out of 100, and 2
out of 100 PCR reactions were positive. With an input of
3  105, 1.8  105, 1.5  105, or 1.2  105 cells per
reaction this points to a proviral DNA load of 0.5, 0.3, 0.5,
and 0.2 copies per 106 PBMC for subjects 1–4,
respectively. Positive PCR results as a consequence of
contamination were excluded by including a comparable
number of DNA samples isolated from blood of healthy
HIV-negative blood donors which all tested negative in the
same PCR analyses (data not shown). In addition, multiple
water controls included randomly in the experiments also
always tested negative (data not shown).
Genetic analyses
Subjects 1, 2, and 4 were homozygous for the CCR5
wild-type allele, whereas subject 3 was heterozygous for the
CCR5 D32 allele (Table 1). None of the four individuals had
mutations in the CCR5 promoter region or carried a CCR2
64I allele. The percentage of CCR5 expressing CD4+ cells
was relatively high in subjects 1, 2, and 4 (Table 1) and in
the normal range in subject 3, as compared to a panel of
HIV-negative individuals (median 15%, range 7–23%) (De
Roda Husman et al., 1999).
Complete HLA typing of the study subjects is presented
in Table 1. Subjects 1, 2, and 4 were all carriers of the HLA-
B*57 allele, which has been strongly associated with
delayed HIV-1 disease progression (Kaslow et al., 1996;
Migueles et al., 2000). Subjects 1 and 4 additionally carried
the HLA-B*3501 allele. HLA-B*35 but not the HLA-
B*3501 subtype has been associated with accelerated
disease progression (Gao et al., 2001). Subject 3 carries
the HLA-B*58 allele, which is closely related to HLA-B*57
but not strongly associated with protection, and an HLA-
Cw7 allele, previously associated with long-term non-
progression (Nehete et al., 1998).
PBMC susceptibility to HIV-1
The relative in vitro HIV-1 susceptibility of the study
subject’s PBMCs was compared with the in vitro suscept-
ibility of PBMCs of control individuals. TCID50 values
obtained with a single virus stock on different target cells
were considered to reflect relative HIV susceptibility of
target cells.
In vitro HIV-1 susceptibility of PBMC of all study
subjects, as reflected by the TCID50 of R5, R5X4, or X4HIV-1 virus clones on CD8-depleted PBMC in vitro, was
significantly lower than the susceptibility of CD8-depleted
PBMC of healthy blood donors (Fig. 2). The median
TCID50 values of all virus variants were 2.0, 2.1, 3.1, and
2.0 log10 on PBMC of subjects 1–4, respectively. The
median TCID50 value of the same virus variants on
PBMC of healthy control individuals and on pooled
PBMC from 10 donors was 3.7 log10, which was
significantly higher as compared to each of the TCID50
values that were established on the PBMC of subjects 1–
4 (P  0.001 for subjects 1, 2, and 4 and P = 0.01 for
subject 3).
HIV-specific cellular immunity
To analyze a possible role for HIV-specific T cells in
controlling HIV-1 infection, PBMC from subjects 1 to 4
were assessed for HIV-specific CD8+ T cell IFNg
responses after stimulation with 5 previously defined
HLA-B57-restricted peptides (Altfeld et al., 2003) using
IFNg-ELIspot assays. All subjects responded to two or
more of the HLA-B*57-restricted peptides (Fig. 3A).
Subject 1 responded to all 5 peptides tested (0.09–0.94%
IFNg-producing CD8+ T cells), subject 2 responded to
the p24 epitopes B57-IW9 and B57-KF11 (0.22% and
0.28% IFNg-producing CD8+ T cells, respectively).
Subject 3 showed a response to the RT epitope B57-
Fig. 3. Analysis of HIV-specific cellular immunity in PBMC. (A)
Percentage of IFNg-producing CD8+ T cells of total CD8+ T cells after
stimulation with B*57-IW9 (ISPRTLNAW), B57-KF11 (KAFSPEVIPMF),
B*57(B58)-TW10 (TSTLQEQIGW) (all based on p24 gag sequences),
HLA-B*57-HQ10 (HTQGYFPDWQ, based on nef sequences), or the
HLA-B*57-restricted RT-based peptide B*57-IW9 (IVLPEKDSW). (B)
FACS analysis of HLA-B*57-restricted HIV-specific CD8+ T cells of
PBMC from subject 1 after staining with tetrameric complexes loaded with
HIV-1 RT peptide IVLPEKDSW (B*57-IW9) or the HIV-1 p24 gag peptide
KAFSPEVIPMF (B*57-KF11). The percentage HLA-B*57-restricted HIV-
1-specific CTL of total CD8+ T cells is indicated. (C) Phenotypic analysis
of HLA-B*57-restricted HIV-specific CD8+ T cells. Percentages of HIV-
specific T cells with a naı¨ve (CD45RO CD27+), memory (CD45RO+
CD27+), memory/effector (CD45RO+ CD27), or differentiated effector
(CD45RO CD27) phenotype are depicted in the upper right corner of the
bottom graphs.
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0.55% of CD8+ T cells, respectively). Subject 4
responded to p24 epitope B57-IW9 and B57-KF11 (both
0.02% of CD8+ T cells).
To confirm the observed IFNg responses, we also
directly visualized HLA-B57-restricted HIV-specific CD8+
T cells using the RT epitope HLA-B*57-IW9 or B*57-KF11 tetrameric complexes. HLA-B*57 tetramer binding
CD8+ T cells were present in all 4 individuals (subject 1:
B*57-IW9: 0.49%, B*57-KF11: 0. 92%; subject 2: B*57-
IW9: 0.39%, B*57-KF11: 1.24%; subject 3: B*57-IW9:
0.18%, B*57-KF11: 0. 27%; subject 4: B*57-IW9:
0.34%, B*57-KF11: 0. 37%; representative staining,
subject 1, Fig. 3B). These frequencies were in the
normal range for HIV-1-infected HLA-B*57 individuals
(0.1%–7.4%; Kostense et al., 2001). In subject 1, 10% of
B*57-IW9 tetramer binding CD8+ cells were negative for
CD45RO and CD27, indicative of a fully differentiated
effector phenotype. Within the subset of B*57-KF11
binding cells, the proportion of CD45RO CD27
effector cells was at most 2% whereas 38% of the
HIV-specific T cells had a CD45RO+ CD27 memory
effector phenotype (Fig. 3C).
Stimulation of PBMC with an overlapping HIV gag
peptide pool revealed the presence of HIV-specific CD3+
CD4+ T cells with proliferative capacity in subjects 2
(0.07% proliferating CD4+ T cells), 3 (1.3% proliferating
CD4+ T cells), and 4 (8.18% proliferating CD4+ T cells)
(Fig. 4A). Polyclonal stimulation revealed good prolifer-
ative capacity of CD3+ CD4+ T cells in all subjects (Fig.
4A). Intracellular staining for cytokine production by CD4+
T cells upon stimulation with an overlapping HIV-1 gag
peptide pool revealed single IFNg-producing CD4+ T cells
(Fig. 4B) in subjects 1, 3, and 4 with percentages of 0.04%,
0.07%, and 0.06%, respectively. Single IL-2-producing
CD4+ T cells were detectable in subjects 1 (0.05%), 2
(0.04%), and 4 (0.03%). CD4+ T cells that produced both
IL-2 and IFNg were detectable in all subjects (subject 1:
0.05%; subject 2: 0.03%; subject 3: 0.04%; subject 4:
0.07%). These values are in the normal range for HIV-1-
infected individuals (Boaz et al., 2002) and are above the
level of gag-induced cytokine production in HIV-negative
individuals (median IFNg+ CD4+ T cells 0.02%, median IL-
2+ CD4+ T cells 0.02%, median IL-2+ IFNg+ CD4+ T cells
0.02%; data not shown).
Serum neutralization of HIV-1
Sera of all four individuals neutralized both an R5 and an
X4 primary HIV-1 variant (Fig. 5). Serum dilutions that
established 90% inhibition (IC90) of R5 and X4 HIV
replication was 2  103 for subject 1 and 4  104 for
subject 2. Sera from subjects 3 and 4 had less potent HIV-1-
neutralizing activity. The IC90 values for the serum of
subject 3 were 5  102 and 6.7  102 and for the serum
of subject 4 1.3  102 and 2.9  102, for the R5 and X4
virus, respectively. Addition of monoclonal antibodies
directed against h-chemokines had no effect on the
neutralizing activity (data not shown), excluding a strong
contribution of h-chemokines in the inhibitory effect.
Adsorption of immunoglobulins from the sera with protein
A (immobilized on Sepharose CL-4B, Sigma) completely
abrogated the neutralizing effect from the sera (data not
Fig. 4. Percentages CD4+ T cells that proliferate (A) or that produce IFNg, IL-2, or both IFNg and IL-2 (B) within the total CD4+ T cell pool of subjects 1–4
after stimulation of the cells with an overlapping HIV-1 gag peptide pool (left panel) or after stimulation with a-CD3/aCD28 (for proliferation, top right) or
PMA (for cytokine production, bottom right). From the presented frequencies first the frequencies obtained in medium controls were subtracted.
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indeed mediated by antibodies.Discussion
We have identified four unique individuals who are
strongly seropositive for HIV-1 antibodies but who have
extremely low levels of proviral DNA which are undetect-
able in routine diagnostic PCR. Three of these individualsFig. 5. Analysis of the HIV-1-specific neutralization activity in sera of study subj
biological virus clone X1.A1 from subject ACH208 (X4). For reference, neutraliza
relative to the cultures without a neutralizing agent. X-axis: dilution of serum.are known to have HIV antibodies for more than 13–22
years. These patients can be distinguished from LTNP
individuals in that they have extremely low levels of
proviral DNA.
The apparently controlled HIV-1 infection in these
individuals is associated with HLA type, a reduced in vitro
HIV-1 susceptibility of their PBMC, and detectable HIV-
specific humoral and cellular immunity. Although it is likely
that these immune responses contribute to the apparently
controlled HIV-1 infection, it cannot be excluded that theseects. Serum-neutralizing activity was measured on HIV-1 JR-CSF (R5) and
tion by HIVIg was analyzed. Y-axis: percentage inhibition of p24 production
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restricted replication in our subjects. Indeed, the preserved
subject’s CD4+ T cell proliferative capacity and/or IL-2 and/
or IFNg production in response to a gag peptide pool has
been associated with low viral load (Jansen et al., submitted
for publication).
HLA-B*57 and B*58 are both members of the relatively
rare HLA supertype family B58s. It has been proposed that
rare HLA alleles are associated with low viral load related to
CTL adaptation of the incoming virus (Scherer et al., 2004).
Second, HLA-B*57 viral escape variants may be severely
attenuated because of structural constraints (Kaslow et al.,
1996; Leslie et al., 2004), indeed resulting in a low viral
load.
In all individuals the presence of HIV-specific CTL, HIV-
specific CD4+ T-helper responses, as well as HIV-specific
antibody-mediated neutralization were observed, to the
same level as previously reported for LTNP with HIV-1
infection. LTNP, however, always have well-detectable
proviral DNA (Wang et al., 2002; Rosenberg et al., 1997;
Cao et al., 1995), indicating that control of HIV-1 infection
to a level of nearly undetectable virus DNA load requires
additional protective mechanisms.
One can envision that HIV-specific immunity may only
be sufficient to fully control low-level viremia and that
severely restricted viral replication may be the primary
cause for their asymptomatic extremely low viremic
infection. Previous reports have indicated that deletions in
HIV-1 structural or accessory genes may result in attenu-
ation of viral replication and consequently a low viral load
and long-term asymptomatic survival (Binley et al., 1998;
Rhodes et al., 2000; Deacon et al., 1995; Kirchhoff et al.,
1995; Mariani et al., 1996; Michael et al., 1995; Huang et
al., 1998a; Wang et al., 1996). As we were unable to isolate
HIV-1 from our study subjects the fitness of the HIV-1
variants could not be established. Moreover, the extreme
low proviral DNA copy number in these individuals
prevented an analysis of accessory gene sequences. Notably,
in all reported cases infected with attenuated HIV-1 due to
deletions in accessory genes, proviral DNA load was
apparently high enough to be analyzed, emphasizing the
uniqueness of the individuals we have studied here. The
partners who infected subjects 2 and 3 both died of AIDS.
This implicates that subjects 2 and 3 were infected by a
virus variant that originated from replication competent viral
quasi-species although selective transmission of an attenu-
ated HIV variant cannot be excluded.
The HIV infection phenotype of the individuals under
study here may also be determined by host factors. PBMC
of all individuals had a strongly reduced susceptibility to
both R5 and X4 HIV-1 infection in vitro, which may be
extrapolated to only very low-level virus replication in vivo.
The underlying mechanism for the reduced HIV-1 suscept-
ibility remains to be established but it is tempting to
speculate that innate immune mechanisms may be involved.
Others have demonstrated replication incompetent HIV-1due to G-A hypermutations in LTNP (Wang et al., 2003;
Huang et al., 1998b), which may indeed point to a role for
APOBEC3g in innate immune control of HIV replication in
LTNP (Sheehy et al., 2002; Lecossier et al., 2003; Mangeat
et al., 2003; Zhang et al., 2003). However, we did not
observe any mutations in the APOBEC3g gene of subjects
2–4 (data not shown). Subject 1 had a 275 Gln to Glu
substitution (data not shown) which was recently described
not to be associated with a differential clinical course of
infection as compared to individuals with the consensus
APOBEC3g sequence (Do et al., 2005).
An intriguing hypothesis might be that the individuals
studied here have eradicated HIV-1 and that the extreme
low-level proviral DNA just represents replication incom-
petent virus as a remainder of an experienced transient HIV-
1 infection. However, sustained virus-specific humoral and
cellular immunity is considered to depend on continuous
low-level HIV-1 replication (Ferbas et al., 1995). The HIV-
specific immunity in the individuals in this study thus may
be considered a token of ongoing antigen exposure because
of low-level viral replication. Although virus could not be
isolated our data thus are not compatible with complete
eradication of the virus. It has been reported that decreases
in viral load during HAART coincide with loss of HIV-
specific immunity (Kostense et al., 2002a, 2000b; Casazza
et al., 2001). The controlled HIV infection in our study
subjects has most likely prevented severe damage to the
immune system which may occur normally during the
period of untreated HIV infection prior to HAART. Under
these conditions very low-level HIV antigen is apparently
sufficient for sustained immunity.
We are currently investigating the frequency of individ-
uals with HIV who control their infection. Estimates based
on an analysis of the Amsterdam Cohorts and the HIV-
infected patient population in the Netherlands allow a rough
estimation of 1 per 2000 HIV-1-infected individuals.
Here we have provided the first evidence of individuals
with apparently abortive HIV-1 infection. The underlying
mechanism for this unique outcome of infection seems to
depend not only on HIV-specific immunity but also most
strongly on the host susceptibility for HIV-1. Effects of
therapeutic vaccination, which will only boost HIV-specific
antiviral immunity, may therefore be limited. Insight into the
exact mechanism underlying the reduced HIV-1 suscepti-
bility may provide interesting new clues for the design of
vaccines and new therapeutic approaches.Materials and methods
Subjects
Several weeks after a self-reported unprotected homo-
sexual contact, a Caucasian male born in 1955 (subject 1)
was admitted to the hospital in 1983 with a clinical picture
compatible with acute retroviral syndrome, which com-
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lymphadenopathy without a skin rash. At that time, no
diagnosis was made and the individual completely recov-
ered without any therapy. The first HIV-1 test was
performed in 1991 on the individuals’ own request. The
presence of HIV-1 antibodies was demonstrated by ELISA
and confirmed by Western blot analysis (Fig. 1).
Subject 2, an Afro-American woman born in 1961, was
diagnosed HIV-1 antibody seropositive in 1992 during
pregnancy of her third child. Her only HIV-risk factor was
unprotected sexual contact during 1982–1989 with her
HIV-infected partner who died of AIDS in 1989. Her
children and new partner have all remained seronegative for
HIV-1 antibodies.
Subject 3, a Caucasian male born in 1962, was diagnosed
to be seropositive for HIV-1 antibodies in 1992. His only
self-reported exposure to HIV-1 had been in 1990 during
unprotected sexual contact with an HIV-1-infected man,
who was treated at that time with zidovudine and died of
AIDS in 1992.
Subject 4, an Afro-American male born in 1954, was
diagnosed seropositive for HIV-1 antibodies by ELISA and
Western blot in 2000. There were no self-reported risk
factors or a more accurate estimation of the time point of
infection.
Serological and virological diagnostic testing
HIV-1 RNA levels in plasma were quantified using the
NucliSense HIV-1 QT assay (Organon Teknika, Boxtel, The
Netherlands) and the Versant HIV-1 RNA 3.0 Assay
(branch-DNA, Bayer Health Care). Proviral DNA was
measured with the Amplicor HIV-1 Test (Roche Molecular
Systems, Branchburg, NJ). Serologic analyses, including
p24 antigen detection, were performed with the Genelabs
Diagnostics HIV BLOT 2.2, Liatek HIV III (Organon
Teknika, Boxtel, The Netherlands), HIV-1/HIV-2 3rd gen-
eration plus EIA, and HIVAG-1 Monoclonal (Abbot
Laboratories Division, Abbot Park, IL). All commercial
tests were performed strictly according to the instructions of
the manufacturer.
Quantification of replication competent HIV from HLA-DR
CD4+ T cells
Quantification of the reservoir of latently HIV-1-infected
HLA-DR CD4+ T cells was performed according to a
modification of the method described by Finzi et al. (van Rij
et al., 2002; Finzi et al., 1997). In brief, peripheral blood
mononuclear cells (PBMC) were isolated by Ficoll density
gradient centrifugation. CD4+ T cells were positively
selected using anti-CD4-coated magnetic beads (MACS
CD4 multisort kit, Miltenyi biotec, Bergisch Gladbach,
Germany) and subsequently depleted for HLA-DR+ cells
using anti-HLA-DR-coated magnetic beads. HLA-DR
CD4+ T cells were stimulated in vitro with irradiatedallogeneic healthy donor PBMC in the presence of 1 Ag/
ml phytohemagglutinin (PHA; Murex Biotech, Dartford,
England) and recombinant human interleukin-2 (rhIL-2,
proleukin; Chiron Benelux BV, Amsterdam, The Nether-
lands). After overnight stimulation, cells were washed and
co-cultivated (103 to 3  104 cells/well, 48 or 96 wells per
cell number per subject) with pooled PHA-stimulated
PBMC (105/well in 96-well plates) of at least ten healthy
donors. Cells were cultured for 28–42 days in Iscove’s
Dulbecco’s Modified Medium (IMDM) (BioWhittaker,
Verviers, Belgium) supplemented with 10% fetal calf serum
(FCS; HyClone, Logan, Utah), 20 U/ml rhIL-2, penicillin
(10 U/ml), and streptomycin (10 Ag/ml).
Every week for a total period of 28–42 days, culture
supernatants were tested for the presence of p24 in an in-
house antigen-capture ELISA (Tersmette et al., 1989). At
the same time, one-third of the cell culture was transferred to
new 96-well plates, and 105 fresh donor PHA–PBMC were
added to propagate the culture.
Host genetic analyses
Genotyping of HLA class I loci was performed with
sequence-specific primers (SSP)–PCR as described else-
where (Cao et al., 2001). The CCR2 and CCR5 genotypes
of the individuals were respectively determined by restric-
tion fragment length polymorphism (RFLP) PCR analysis
and PCR analysis using primers flanking the 32-base pair
deletion in CCR5, as described in detail elsewhere (De Roda
Husman et al., 1997; van Rij et al., 1998). The CCR5
promoter regions from DNA of our study subjects were
amplified and sequenced using primers 627T-1 and 627T-2
primers as described previously (Mummidi et al., 1998).
Flow cytometry
The expression levels of the HIV-1 co-receptors were
determined by four-color flow cytometry. PBMCs from
each subject were stained with monoclonal antibodies
directed against CCR5 (clone 2D7, FITC conjugated;
Pharmingen San Diego, CA), CXCR4 (clone 12G5, PE
conjugated; Pharmingen), CD45RO (APC conjugated;
Becton Dickinson (BD), San Jose, CA), and CD4 (PerCP
conjugated; BD). Incubation was performed for 20 min at
4 -C. Flow cytometry analyses were performed on a
FACScaliber (BD). CCR5 and CXCR4 expressions were
determined on gated lymphocytes and on CD45RO+ and
CD45RO CD4+ T cells.
In vitro HIV-1 susceptibility of PBMC
The 50% tissue culture infectious dose (TCID50) of a
panel of R5, R5X4, and X4 HIV-1 variants was determined
on CD8-depleted, 3-day PHA-stimulated PBMC of the
study subjects and healthy blood donor volunteers (Blaak et
al., 1998). Briefly, cryopreserved PBMC of study subjects
N. Kloosterboer et al. / Virology 339 (2005) 70–80 77and healthy blood donor volunteers were thawed and
stimulated in IMDM supplemented with 10% FCS and 1
Ag/ml PHA for 3 days (5  106 cells/ml) and were depleted
for CD8+-positive cells using magnetic beads (MACS
Miltenyi biotec, Bergisch Gladbach, Germany). On these
cells we titrated cell-free HIV-1 stocks from the R5 HIV-1
strain JR-CSF, R5X4 HIV-1 biological virus clone 13B1,
and X4 biological virus clone X1.A1 from subject ACH208
(van Rij et al., 2000), R5X4 HIV-1 biological virus clone
3.1 from subject ACH320 (Groenink et al., 1991), R5X4
HIV-1 strain HAN2 (Sauermann et al., 1990), and X4 HIV-1
isolate IIIB. Eight days after inoculation, virus production in
culture supernatants was analyzed with an in-house p24
ELISA (Tersmette et al., 1989) and the TCID50 was
calculated. TCID50 values obtained with a single virus
stock on different target cells were considered to reflect
relative HIV susceptibility of target cells and were
compared with the Mann–Whitney U test, using SPSS
10.0 for windows (SPSS Inc., Chicago, Illinois, USA).
HIV-1-specific cellular immunity
HLA class I monomers complexed with HIV-specific
peptides were produced as previously described (Altman
et al., 1996). The HIV-1 RT peptide IVLPEKDSW (B*57-
IW9) or the HIV-1 p24 gag peptide KAFSPEVIPMF
(B*57-KF11) (Dutch Cancer Institute, Amsterdam, The
Netherlands) was complexed with HLA-B*5701 proteins.
Refolded HLA peptide monomeric complexes were bio-
tinylated and subsequently tetramerized by addition of
allophycocyanin streptavidin. Four-color fluorescence anal-
ysis was performed (Kostense et al., 2002a, 2000b; van
Baarle et al., 2002). Briefly, PBMC were thawed and 2 
106 cells were stained with the APC-conjugated tetramer
for 20 min at room temperature, and with the fluoro-
chrome-conjugated monoclonal antibodies CD8-PerCP,
CD27-PE, and CD45RO-FITC (BD). Cells were fixed in
Cellfix (BD) and at least 250,000 events were acquired
using FACSCalibur flow cytometer (BD). Lymphocytes
were gated by forward and sideward scatter. Data were
analyzed using the software program CELL Quest (BD).
ELIspot assay for single cell IFNc release
IFNg-producing virus-specific CD8+ T cells were enum-
erated using IFNg-specific ELIspot assays as previously
described (van Baarle et al., 2001; Lalvani et al., 1997),
using 96-well nylon-backed plates (Nunc, Roskilde, Den-
mark) and IFNg-specific monoclonal antibodies (MAB-
TECH, Stockholm, Sweden). PBMC were thawed and
incubated in triplicate (105 cells/well) in the absence or
presence of 10 Ag/ml HLA-B*57-restricted peptides B*57-
IW9 (ISPRTLNAW), B57-KF11 (KAFSPEVIPMF),
B*57(B58)-TW10 (TSTLQEQIGW) (all based on p24 gag
sequences), HLA-B*57-HQ10 (HTQGYFPDWQ, based on
nef sequences), or the HLA-B*57-restricted RT-basedpeptide B*57-IW9 (IVLPEKDSW) and incubated overnight
at 37 -C. PHA stimulation served as a positive control to test
the capacity of PBMC to produce IFNg in general. IFNg-
producing cells were detected as dark spots and counted
using an automated spot reader (AEL.VIS., Software
version 3.2, Hanover, Germany). HIV-1-specific IFNg
responses were reported as percentage of IFNg-producing
CD8+ T cells based on the spot forming units per million
PBMC and corrected for the percentage CD8+ T cells in the
PBMC. Only samples with frequencies of SFU that were
higher than the frequencies of SFU in medium controls were
considered positive. From the data presented the frequencies
of SFU obtained in medium controls were subtracted.
Detection limit of the ELIspot assay is 1 spot per 105
implicating that after subtraction of the SFU in the medium
controls frequencies of >0.001% HIV-specific CD8+ T cells
can be detected.
Intracellular cytokine staining after antigenic stimulation
In vitro T cell proliferation after stimulation with HIV
peptide pools was measured using the fluorescent, cell
permeable dye CFSE (5,6-carboxyfluorescein diacetate
succinimidyl ester; Molecular Probes, Leiden, The Nether-
lands) according to the manufacturer’s protocol. Briefly,
cryopreserved PBMC were thawed and cells were incubated
with CFSE for 8 min after which labeling was stopped using
human pool serum (HPS). Cells were washed and aliquoted
at 2  106 cells per 0.5 ml RPMI-1640 medium in round
bottom tubes (polystyrene, Falcon, BD) and stimulated with
a gag-derived peptide pool (15-mers with 11 amino acids
overlap, HXB2, AIDS Reagents, Bethesda, MA; concen-
tration of the individual peptides within each pool was 2 Ag/
ml). As a positive control, cells were stimulated with a
combination of 0.4 Ag/ml aCD3 and 4 Ag/ml aCD28
(Sanquin Reagents, Amsterdam, The Netherlands). After 6
days of incubation at 37 -C, 5% CO2, cells were stained
using CD4-APC and CD3-PerCP monoclonal antibodies
(BD) and analyzed using a FACSCalibur. Percentage
proliferating CD4+ CD3+ T cells (CFSElow cells) of the
total CD4+ CD3+ T cell pool was calculated.
For the staining of intracellular cytokines, thawed cells
were stimulated with the same gag peptide pool for 6 h at
37 -C, 5% CO2, and co-stimulated with aCD28 (2 Ag/ml;
Sanquin Reagents, Amsterdam, The Netherlands) and
aCD49d (2 Ag/ml; Pharmingen, San Jose´, CA). As a
positive control, stimulation with PMA/Ionomycin was
performed. After 1 h, Brefeldin A (BD) was added to block
extracellular secretion of cytokines. After incubation, cells
were fixed, permeabilized (permeabilization kit, BD) and
stained with aCD3-PerCP, aCD4-APC, aIL-2-PE, and
aIFNg-FITC (BD) for 20 min at 4 -C. Cells were then
fixed in Cellfix (BD) and at least 300,000 events were
acquired using a FACSCalibur flow cytometer (BD).
Lymphocytes were gated by forward and sideward scatter.
Data were analyzed using the software program CELL
N. Kloosterboer et al. / Virology 339 (2005) 70–8078Quest (BD). From the reported frequencies of IFNg and IL-
2 forming cells, the frequencies of IFNg- and IL-2-
producing cells obtained in medium controls were first
subtracted.
Serum neutralization of HIV-1
Heat-inactivated sera obtained from study subjects and
four healthy donors and HIVIg were compared for
neutralizing capacity (Beaumont et al., 2000) of R5 HIV-1
variant JR-CSF and X4 HIV-1 biological virus clone X1.A1
from subject ACH208 (van Rij et al., 2000). From each
virus isolate, an inoculum of 100 TCID50/ml in a 100-Al
final volume was incubated for 2 h at 37 -C with increasing
concentrations of serum, or with HIVIg. Subsequently, 105
PHA-stimulated human PBMC were added to the virus–
serum and virus–HIVIg mixtures in 96-well microtiter
plates up to a final volume of 200 Al. At day 1, cells were
washed to remove input p24 antigen, and refed with fresh
IMDM medium supplemented with 10% FCS, 20 U/ml IL-
2, and antibiotics. On days 7 and 14, supernatants were
analyzed for evidence of virus production using an in-house
p24 antigen capture ELISA (Tersmette et al., 1989).
Neutralization was calculated as the percent reduction in
p24 production in the presence of serum or HIVIg as
compared to the p24 production in cultures with virus only.
The 90% inhibitory concentrations (IC90) were determined
by linear regression.Acknowledgments
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